These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32990313)

  • 1. Vascular toxicity associated with anti-angiogenic drugs.
    Neves KB; Montezano AC; Lang NN; Touyz RM
    Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.
    Neves KB; Rios FJ; Jones R; Evans TRJ; Montezano AC; Touyz RM
    Cardiovasc Res; 2019 Apr; 115(5):978-988. PubMed ID: 30753341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of PARP and TRPM2 in VEGF Inhibitor-Induced Vascular Dysfunction.
    Neves KB; Alves-Lopes R; Montezano AC; Touyz RM
    J Am Heart Assoc; 2023 Feb; 12(4):e027769. PubMed ID: 36802924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
    Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
    Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
    Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
    Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M
    PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
    Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
    Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
    Thanigaimani S; Kichenadasse G; Mangoni AA
    Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
    Adjei AA
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S74-8. PubMed ID: 17382028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes.
    Neves KB; Rios FJ; van der Mey L; Alves-Lopes R; Cameron AC; Volpe M; Montezano AC; Savoia C; Touyz RM
    Hypertension; 2018 Apr; 71(4):638-647. PubMed ID: 29483228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA; Verweij J
    Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
    van Dorst DCH; van Doorn L; Mirabito Colafella KM; Manintveld OC; Hassing HC; Danser AHJ; Mathijssen RHJ; Versmissen J
    Clin Sci (Lond); 2021 Jul; 135(14):1649-1668. PubMed ID: 34283204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
    Kerbel RS; Viloria-Petit A; Klement G; Rak J
    Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.